Production of β-Lactamase Inhibitors by Streptomyces Species
Abstractβ-Lactamase inhibitors have emerged as an effective alternative to reduce the effects of resistance against β-lactam antibiotics. The Streptomyces genus is known for being an exceptional natural source of antimicrobials and β-lactamase inhibitors such as clavulanic acid, which is largely applied in clinical practice. To protect against the increasing prevalence of multidrug-resistant bacterial strains, new antibiotics and β-lactamase inhibitors need to be discovered and developed. This review will cover an update about the main β-lactamase inhibitors producers belonging to the Streptomyces genus; advanced methods, such as genetic and metabolic engineering, to enhance inhibitor production compared with wild-type strains; and fermentation and purification processes. Moreover, clinical practice and commercial issues are discussed. The commitment of companies and governments to develop innovative strategies and methods to improve the access to new, efficient, and potentially cost-effective microbial products to combat the antimicrobial resistance is also highlighted. View Full-Text
Share & Cite This Article
Viana Marques, D.D.A.; Machado, S.E.F.; Ebinuma, V.C.S.; Duarte, C.D.A.L.; Converti, A.; Porto, A.L.F. Production of β-Lactamase Inhibitors by Streptomyces Species. Antibiotics 2018, 7, 61.
Viana Marques DDA, Machado SEF, Ebinuma VCS, Duarte CDAL, Converti A, Porto ALF. Production of β-Lactamase Inhibitors by Streptomyces Species. Antibiotics. 2018; 7(3):61.Chicago/Turabian Style
Viana Marques, Daniela D.A.; Machado, Suellen E.F.; Ebinuma, Valéria C.S.; Duarte, Carolina D.A.L.; Converti, Attilio; Porto, Ana L.F. 2018. "Production of β-Lactamase Inhibitors by Streptomyces Species." Antibiotics 7, no. 3: 61.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.